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Abstract
Background: Adult patients receiving anti-TNFα drugs are at increased risk of tuberculosis (TB), but studies in
pediatric populations are limited, and the best strategy for latent tuberculosis infection (LTBI) screening in this
population remains controversial. We describe the prevalence of LTBI prior to anti-TNFα therapy and the long-term
follow-up after biological treatment initiation in a cohort of children and adolescents.
Methods: Cohort observational study in children and adolescents receiving anti-TNFα agents in a tertiary-care
pediatric hospital. LTBI was ruled out prior to the implementation of anti-TNFα drugs by tuberculin skin test (TST),
and, from March 2012 on, QuantiFERON Gold-In Tube® test (QTF-G). During anti-TNFα treatment, patients were
evaluated every 6 months for TB with history and physical examination. TST/QTF-G were not repeated unless signs
or symptoms consistent with TB arose or there was proven TB contact.
Results: The final cohort consisted of 221 patients (56.1 % female; 261 treatments), of whom 51.7 %/30.0 %/17.3 %
were treated with etanercept/adalimumab/infliximab, respectively, for a variety of rheumatic diseases (75.6 %),
inflammatory bowel disease (20.8 %), and inflammatory eye diseases (3.6 %). The median (IQR) age at diagnosis of the
primary condition was 6.8 years (2.7–11.0) and the duration of the disease before implementing the anti-TNFα agent
was 1.8 years (0.6–4.2). LTBI was diagnosed in 3 adolescent girls (prevalence rate: 1.4 %; 95 % CI: 0.4–4.2) affected with
juvenile idiopathic arthritis: TST tested positive in only 1, while QTF-G was positive in all cases (including 2 patients
already on etanercept). They all received antiTB chemoprophylaxis and were later (re)treated with etanercept for 24–29
months, without incidences. No incident cases of TB disease were observed during the follow-up period under anti-
TNFα treatment of 641 patients-year, with a median (IQR) time per patient of 2.3 years (1.4–4.3).
Conclusions: In our study, the prevalence of LTBI (1.4 %) was similar to that reported in population screening studies
in Spain; no incident cases of TB disease were observed. In low-burden TB settings, initial screening for TB in children
prior to anti-TNFα treatment should include both TST and an IGRA test, but systematic repetition of LTBI
immunodiagnostic tests seems unnecessary in the absence of symptoms or known TB contact.
Keywords: Inflammatory bowel disease, Interferon-gamma release assays, Juvenile idiopathic arthritis, Tuberculosis,
Anti-tumor necrosis factor-alpha drugs
* Correspondence: ton@hsjdbcn.org
6Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan
de Déu, Universitat de Barcelona, Passeig Sant Joan de Déu 2, 08950
Esplugues de Llobregat, Spain
Full list of author information is available at the end of the article
© 2015 Calzada-Hernández et al. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Calzada-Hernández et al. Pediatric Rheumatology  (2015) 13:54 
DOI 10.1186/s12969-015-0054-4
Background
Anti-tumour necrosis factor alpha (TNFα) agents repre-
sent a major advance in the treatment of several auto-
immune and autoinflammatory diseases, both in children
and in adults. TNFα plays a critical role in the host re-
sponse to tuberculosis (TB), having an essential role in the
formation of the granuloma. Exposure to anti-TNFα drugs
has been associated with reactivation of latent TB infec-
tion (LTBI) in adulthood, even after discontinuation of the
treatment [1–3]. Therefore, current guidelines recom-
mend screening for LTBI before anti-TNFα treatment
implementation [2]. In children and adolescents on anti-
TNFα therapy, data are still scarce and questions about
the best strategy for LTBI screening and the risk of TB re-
main unanswered [4].
Our aims were to assess the prevalence of LTBI in a co-
hort of children and adolescents expected to be treated
with anti-TNFα agents and to describe the incidence of
TB during follow-up while on anti-TNFα treatment.
Methods
We conducted a retrospective observational study in a
large cohort of patients aged <18 years treated with anti-
TNFα agents for a variety of inflammatory diseases in a
tertiary-care pediatric centre (Hospital Sant Joan de Déu,
Barcelona) from December 2004 to January 2013, in
Catalonia (Northeast Spain). The incidence rate of TB in
Catalonia has decreased from 21.6 per 100,000 popula-
tion in 2004 to 16.3 in 2012. Because anti-TNFα agents
are hospital-prescribed drugs, patients were identified
using centralized pharmacy records. Exclusion criteria
were: 1. previous history of LTBI and/or TB; 2. previous
exposure to anti-TNFα drugs; 3. follow-up time <3 months
since anti-TNFα drug implementation; and 4. anti-TNFα
treatment first prescribed elsewhere. Patients for whom
complete data on LTBI screening could not be retrieved
were not included in the analysis of LTBI prevalence.
The following demographic and clinical variables were
collected: age, gender, primary disease, time from diag-
nosis until start of anti-TNFα drug, and type and dur-
ation of anti-TNFα treatment. All patients are routinely
screened for TB infection before anti-TNFα drug imple-
mentation. Our local protocol includes clinical history
focused on TB risk (immigration from or travel to a high
burden country for TB, known TB contacts, and signs or
symptoms consistent with TB), Bacillus Calmette-Guérin
(BCG) vaccine status, physical examination, tuberculin
skin test (TST), and chest x-ray (CXR). A positive TST
result is defined as a reaction ≥5 mm [5]. BCG vaccine is
not recommended in Spain. As from March 2012, an IGRA
(interferon-gamma release assays) test (Quantiferon-TB
Gold-in Tube® test, QTF-G; Cellestis, Carnegie, Australia)
became available in clinical practice in our centre and was
included in the screening protocol, together with TST.
After initial assessment, patients are clinically re-evaluated
every 3–6 months for TB infection, but CXR and TST/
QTF-G are not routinely repeated in the absence of signs
or symptoms consistent with TB or proven TB contact. In
those patients with negative screening results before March
2012 who were still on anti-TNFα drugs later on, QTF-G
was performed once during clinical follow-up. After exclu-
sion of TB disease, any positive result is taken as evidence
for LTBI and secondary chemoprophylaxis is recom-
mended, as per national guidelines [5]. After 4 weeks of
LTBI prophylaxis, anti-TNFα treatment is implemented if
indicated. The local ethics committee approved the study.
Categorical variables were described as percentages, and
continuous variables as mean/standard deviation (SD) or
median/interquartile ranges (IQR). Finally, we performed
a systematic literature review to find original studies
that evaluated anti-TNFα therapy in human subjects
aged <18 years (English language, years 2000–2014).
We reviewed all references found through PubMed
using a combination of the search terms infliximab
(INF), etanercept (ETN), adalimumab (ADA), and TB.
We then checked the references of each study to find
any missed studies.
Results
From December 2004, a total of 261 anti-TNFα treat-
ments were prescribed to 221 patients (124 females, 97
males). Thirty-six patients switched once and two patients
switched twice to other anti-TNFα drugs, mainly due to
insufficient clinical response. The median (IQR) age at
diagnosis of the primary condition was 6.8 (2.7–11.0)
years and the duration of the disease before implementing
the anti-TNFα agent was 1.8 (0.6–4.2) years. Etanercept
was the most commonly prescribed drug (51.7 %),
followed by ADA (31.0 %) and INF (17.3 %). The total
follow-up time while on anti-TNFα treatment was 614
patient-years; median time on anti-TNFα drug per pa-
tient was 2.3 (1.4–4.3) years (ETN 1.9 [1.8–3.7]; ADA
1.8 [1.2–2.6]; and INF 2.1 [1.4–3.3] years). Juvenile
idiopathic arthritis (JIA) was the most frequent indica-
tion for anti-TNFα treatment (74.7 %, 195 treatments
in 163 patients); other indications included inflamma-
tory bowel disease (19.1 %, 50 treatments in 46 pa-
tients) and idiopathic uveitis (4.2 %, 11 treatments in 8
patients) (Table 1).
Most of the patients were Spanish (197 children,
89.1 %). Among 16 patients from South America and 8
from Morocco, a BCG scar was documented in 13 and 4
children, respectively. Other than immigration from TB-
endemic regions, no other risk factors for TB were identi-
fied. Retrospective chart review documented no abnormal
findings on CXR for 212 patients (95.9 %) and negative
TST results in 209 children (94.6 %); positive TST was
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observed only in patient 3 (Table 2). Baseline CXR and
TST results were not available for 9 and 11 patients,
respectively.
From March 2012, QTF-G was performed in 75 pa-
tients (33.9 %), with positive, negative, and indeterminate
results in 3 (patients 1–3, Table 2), 66, and 6 children,
respectively. Baseline TST was positive in just one of the
3 QTF-G positive patients, all of whom were BCG-
unvaccinated. All indeterminate QTF-G results were due
to low mitogen response. Baseline screening results in
these six patients (median [range] age: 8.6 [7.0-12.9]
years) had previously ruled out LTBI and they were all
on anti-TNFα treatment, associated with methotrexate
in 4 cases. QTF-G was repeated in 4 of the 6 children
with previous indeterminate result and proved negative
in 3 of them, while remaining indeterminate in one.
None of these patients received chemoprophylaxis nor
developed TB after a median (IQR) follow-up of 1.8
(1.6–1.9) years. The other two patients were transferred
to adult care and were lost to follow-up.
Three Spanish girls affected with JIA were diagnosed
with LTBI (prevalence rate: 1.4 %; 95 % confidence inter-
val: 0.4–4.2 %; Table 2). Focused history disclosed no
known risk of TB infection in any of the girls; they had
not received BCG vaccine and no clinical or radiological
evidence of TB was detected. In patient 3, both TST and
QTF-G tested positive before anti-TNFα or any other
immunosuppressive drug was implemented. In patients
1 and 2, baseline TST was negative but QTF-G tested
marginally positive afterwards, when ETN had already
been implemented. When they were diagnosed with
LTBI, the anti-TNFα treatment was discontinued and
anti-TB chemoprophylaxis started, either 9 months of
isoniazid monotherapy or 3 months of isoniazid and ri-
fampicin. All patients adhered properly to the LTBI
chemoprophylaxis regimen and no tolerability problems
were reported. Etanercept was resumed 1 month after
anti-TB chemoprophylaxis implementation; clinical
follow-up while on ETN for 24, 25, and 29 months in
patients 1, 2, and 3, respectively, showed no evidence of
TB reactivation . Overall, after a follow-up of 614
patient-years, no incident cases of TB disease were
observed.
Discussion
In adults, anti-TNFα agents increase the risk of LTBI re-
activation [1–3]. The risk has been described as being
higher with monoclonal antibodies (INF/ADA), as com-
pared with ETN, and times to TB onset from anti-TNFα
drug implementation are shorter with INF (median time:
5.5 months) than with ETN (13.4 months) or ADA
(18.5 months) [1]. In our pediatric cohort, patients
received both monoclonal antibodies and ETN for a me-
dian time of 2.3 years per patient, and no incident TB
disease cases were observed. Both the use of those drugs
Table 1 Primary diseases leading to anti-TNFα treatment imple-
mentation; number (%) of patients in all cases
Primary disease Patients
(n = 221)
Treatments
(n = 261)
Juvenile idiopathic arthritis 163 (73.6) 195 (74.7)
Polyarticular JIA, positive RF 6 (2.7) 7 (3.8)
Polyarticular JIA, negative RF 40 (18.1) 48 (18.4)
Oligoarticular JIA 70 (31.7) 88 (33.7)
Enthesitis-related arthritis 24 (10.9) 24 (9.2)
Psoriasic arthritis 11 (5.0) 13 (5.0)
Undifferentiated disease 12 (5.4) 15 (5.7)
Blau syndrome 1 (0.5) 2 (0.8)
Tumor necrosis factor associated
periodic syndrome
1 (0.5) 1 (0.4)
PAPA syndrome 1 (0.5) 1 (0.4)
Chronic plantar fascitis 1 (0.5) 1 (0.4)
Inflammatory bowel disease
Crohn’s disease 36 (16.3) 39 (14.9)
Ulcerative colitis 10 (4.5) 11 (4.2)
Inflammatory diseases of the eye
Uveitis 7 (3.2) 10 (3.8)
Pars planitis 1 (0.5) 1 (0.4)
JIA juvenile idiopathic arthritis, PAPA pyogenic arthritis, pyoderma
gangrenosum and acne, RF rheumatoid factor
Table 2 Details of the 3 girls affected with juvenile idiopathic arthritis that were diagnosed with latent tuberculosis infection and
received antituberculosis chemoprophylaxis
Pt Age - gender – primary disease TST
(mm)
Treatment at QTF-G
performance
QTF-G IFN-γ
concentrations
(TB antigens-nil)
LTBI
chemoprophylaxis
Maximum
ALT/AST
(IU/L)
Time on anti-TNFα drugs
(before/after LTBI
chemoprophylaxis)
1 11y6m – female-polyarticular JIA,
negative RF
0 ETN +MTX 0.55 IU/mL H for 9 months 30/37 22 (1/24) months
2 10y7m – female -oligoarticular
JIA
0 ETN 0.37 IU/mL HR for 3 months 31/38 29 (14/25) months
3 8y5m – female -oligoarticular JIA 15 NSAIDs 4.78 IU/mL HR for 3 months 25/24 12 (0/29) months
ALT alanine aminotransferase, AST aspartate aminotransferase, H isoniazid, IFN-γ interferon-gamma, MTX methotrexate, NSAIDs non-steroidal anti-inflammatory
drugs, Pt patient, R rifampicin, RF rheumatoid factor
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with the higher risk and the long follow-up time in our
cohort are reassuring.
A systematic review by Toussi et al. identified very few
children on anti-TNFα drugs who developed TB [6],
likely owing to a lower prevalence of LTBI in the
pediatric age and to effective screening of LTBI. Table 3
summarizes all reported cases to date of mycobacterial
disease in children and adolescents exposed to anti-
TNFα agents [3, 4, 7–14]. All cases involved extrapul-
monary TB, and miliary/meningeal TB and death were re-
ported in 5 and 2 patients (out of 11 cases), respectively.
Of note, disease caused by non-TB mycobacterial species
has also been reported after anti-TNFα drug use [13], and
also following in utero exposure to infliximab [14].
To the best of our knowledge, this is the largest pub-
lished cohort of patients aged <18 years treated with
anti-TNFα agents in whom TB infection was investi-
gated, both in terms of number of children and length of
follow-up. The LTBI prevalence rate in our study (1.4 %)
is similar to that reported in the healthy pediatric Spanish
population (0.9 %) [15], and, more importantly, no inci-
dent cases of TB disease were observed. The retrospective
design, the low TB incidence in Catalonia, and the fact
that QTF-G was unavailable until March 2012 are limita-
tions of our study.
Similar studies from Turkey and England have been
published [16–19]. In the Turkish studies, the reported
prevalence rate for LTBI ranged from 4.8 to 19.4 %, and this
was probably overestimated because of false-positive results
due to universal BCG vaccination in Turkey [16–18]. In the
English study, both TST and QTF-G were performed by
INF treatment in 23 children, and only one case of LTBI
was diagnosed [19]. All LTBI cases in these studies received
chemoprophylaxis before anti-TNFα drug implementation,
and no cases of TB were reported, highlighting the import-
ance of LTBI diagnosis and treatment in this group of pa-
tients. In the absence of specific data on the best
chemoprophylaxis regimen for LTBI in these patients,
using the same regimens used in healthy children seems
reasonable [5].
Table 3 Table summarizing cases published to date of mycobacterial disease in patients aged <18 years who were exposed to anti-
TNFα agents
Pt Ref Primary
disease
Anti-TNFα drug Age/
gender
Time
on
drug
Details on mycobacterial disease
Tuberculosis disease
1 [3] JIA Etanercept NR NR Extrapulmonary
2 [3] JIA Etanercept NR NR Extrapulmonary
3 [7] Polyarticular
JIA
Infliximab +MTX NR 2y Asymptomatic miliary TB (MTB PCR positive in sputum) with good
response to 9-month standard treatment
4 [8] Systemic JIA Etanercept→ infliximab + (previous
extensive immunosuppressive
therapy)
9y /
female
NR Subcutaneous cyst on the left wrist, after extensive microbiological
studies, only MTB PCR in cyst fluid was positive. The child died after
fulminant undiagnosed opportunistic pulmonary infection, 1 month
after anti-TB drugs were implemented
5 [9] Systemic JIA Etanercept (previous CT and MTX) 9y /
female
5wk Ankle arthritis with positive MTB culture and normal chest X-ray; good
response to 12-month standard treatment
6 [10] SAPHO
syndrome
Adalimumab (previous CT) 17y /
female
3y Meningeal and miliary TB presenting with septic shock; several PCR
and cultures tested positive for MTB. Good response to therapy, but
for neurologic sequelae. Adalimumab stopped 4 weeks earlier,
suggesting immune reconstitution inflammatory syndrome
7 [11] Polyarticular
JIA
Infliximab (previous MTX) 13y /
male
3 m TB pleuritis (cultures negative) with good response to anti-TB therapy
8 [12] Ulcerative
colitis
Infliximab
(previous CT and azathioprine)
17y /
male
8 m Miliary TB; the patient developed isoniazid-related hepatitis, but
showed good response later on to an isoniazid-free regimen
9 [12] Crohn’s
disease
Infliximab 13y /
female
2y Disseminated TB disease with good response to 9-month standard
therapy
Nontuberculous mycobacterial disease
10 [13] Crohn’s
disease
Infliximab→ adalimumab
(previous CT)
12y /
female
9 m Generalized lymphadenopathies due to culture-proven Mycobacterium
avium complex infection; good response to ethambutol, clarithromycin
and rifampin
11 [14] Mother’s
Crohn
disease
Infliximab during gestation 3 m /
male
36wk
in
utero
Bottle-fed. BCG vaccination at 3 m of age; disseminated BCGitis
leading to death 6 weeks later
BCG bacillus Calmette-Guérin, CT corticosteroids, MTB Mycobacterium tuberculosis, MTX methotrexate, NR not reported, PCR polymerase chain reaction, Pt patient,
Ref reference, SAPHO synovitis acne pustulosis hyperostosis and osteitis
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The best way to screen for LTBI in these patients re-
mains uncertain. Recent studies in adults with immune-
mediated inflammatory diseases have demonstrated that
IGRA tests: a) show a better association with classic risk
factors for LTBI; b) are more specific than TST for the
diagnosis of LTBI, especially among BCG-vaccinated pa-
tients, and therefore decrease the number of LTBI treat-
ments needed; and c) are more sensitive than TST,
probably because they are less affected by concomitant
use of corticosteroids or other immunosuppressive drugs
[20, 21]. Despite this, significant numbers of patients
with discordant positive TST/negative IGRA results in
the absence of BCG vaccination have also been ob-
served [21]. The latest expert recommendations call
for a dual testing strategy including both TST and an
IGRA test in immunosuppressed patients, or even a
dual IGRA strategy in regions using BCG, in order to
maximise sensitivity [22].
For the pediatric age data are still very scarce. In a
large longitudinal series of children with inflammatory
bowel disease (72 patients, 165 QTF-G tests), indeter-
minate QTF-G results (10 %) were associated with cor-
ticosteroid use and several markers of disease activity,
and 4 QTF-G conversions and 5 QTF-G reversions were
identified during follow-up [23]. Similar rates of indeter-
minate IGRA results have been reported by other
authors, and several cases of negative TST/positive
IGRA and even negative/negative results in children
with TB have been described [10, 19]. Interestingly, in
our cohort, LTBI in patients 1 and 2 was only diagnosed
with borderline positive QTF-G results when both girls
were already on ETN. While this may represent false-
positive results, it has also been reported that anti-TNFα
therapy is associated with a higher rate of indeterminate
IGRA results [23]. Given the lack of evidence, we are in
agreement that both TST and at least one IGRA test
should be used in immunosuppressed children, and any
positive result should be taken as evidence of LTBI.
Conclusions
No incident cases of TB disease were observed after a
614 patient-year follow-up in a cohort of children and
adolescents receiving anti-TNFα drugs in a low-
incidence setting. Three girls (1.4 %) were diagnosed
with LTBI; they received anti-TB chemoprophylaxis and
did well upon ETN resumption. Tuberculosis does not
seem to be a prevalent problem in our population, but
severe evolution in the cases reported to date makes
LTBI screening mandatory prior to anti-TNFα drug im-
plementation. Although further data are needed to bet-
ter define the optimal LTBI testing strategy in these
children in low-burden TB settings, initial screening
should include both TST and an IGRA test. However,
systematic repetition of LTBI immunodiagnostic tests
seems unnecessary in the absence of symptoms or
known TB contact.
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